Skip to content

Hypovitaminosis D Prediction Score

SCOPYD Study: Development of a Predictive Clinical Score of Hypovitaminosis D

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02822651
Acronym
SCOPYD
Enrollment
2592
Registered
2016-07-04
Start date
2016-09-19
Completion date
2017-11-17
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Status

Brief summary

Vitamin D has effects on many tissues, and hypovitaminosis D is frequent. In a French survey conducted among 1587 adults, vitamin D insufficiency (\<30ng/ml) has been reported in 80% of subjects, including 43% with moderate deficiency (\<20ng/ml) and 5% with severe deficiency (\<10ng/ml). Because of the possible consequences of hypovitaminosis D (osteomalacia in adults…), the number of vitamin D determination has increased ten-fold since 2005 in France, reaching 4.5 million € in 2011, and with it the costs for health insurance. However, there is currently no consensus on the strategy for detection, diagnosis and treatment of hypovitaminosis D. We propose to develop a predictive clinical score of hypovitaminosis D based on the accurate assessment of solar exposure, vitamin D intakes and hypovitaminosis D risk factors collected through a self-administered questionnaire.

Interventions

BIOLOGICALBlood sampling

Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.

Patients will fill a self-administered questionnaire the day of inclusion

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

\- Men and women aged 18 to 70 years old

Exclusion criteria

* Participation in a study related to vitamin D * Taking at least 80 000 IU vitamin D in the last 3 months as a single dose * Pregnancy or breast-feeding * Renal failure : severe renal impairment, dialysis, having kidney transplant * Known hepatic impairment * Gastrointestinal disorders: Celiac disease, Crohn's disease, ulcerative colitis, bariatric surgery, gastrointestinal surgery with stoma * Known primary hypo/hyperparathyroidism * Bone cancer/metastases current or in the last 2 years * Treatment with antiepileptics * Long-term treatment with glucocorticoids (\> 3 months) * Treatment with antiretroviral * Legal incapacity or limited legal capacity * Non-recipient of French Social Security

Design outcomes

Primary

MeasureTime frameDescription
25 (OH) vitamin D blood concentrationThe day of inclusionVitamin D determination will be carried out for each center in a single laboratory by chemiluminescence technique. Vitamin D determination is the gold standard for the development and validation phases of the score. It will define the variables of the self-administered questionnaire to be included in the final score (development phase) and be the gold standard in the evaluation of the performance score (validation phase). The blood sample will be collected after the completion of the questionnaire, on the same day.

Secondary

MeasureTime frameDescription
Vitamin D concentration levelThe day of inclusionThe ability of the score to classify adults in one of these three categories: * Category 1 : Vitamin D sufficiency (≥30 ng/ml) * Category 2 : Hypovitaminosis D between 30 and 10 ng/ml * Vitamin D insufficiency (\<30 ng/ml) * Vitamin D deficiency (\<20 ng/ml) * Category 3 : Severe deficiency (\<10 ng/ml)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026